Federated Hermes
NMRA icon

Federated Hermes’s Neumora Therapeutics NMRA Stock Holding History

Federated Hermes’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.9K Sell
35,262
-278,857
-89% -$531K ﹤0.01% 1683
2026
Q1 		$613K Hold
314,119
– – ﹤0.01% 1247
2025
Q4 		$562K Hold
314,119
– – ﹤0.01% 1276
2025
Q3 		$572K Hold
314,119
– – ﹤0.01% 1302
2025
Q2 		$230K Buy
314,119
+29,543
+10% +$22.4K ﹤0.01% 1467
2025
Q1 		$285K Buy
+284,576
New +$487K ﹤0.01% 1439

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federated Hermes's NMRA Position: Q2 2026 in Review

Federated Hermes reduced its Neumora Therapeutics (NMRA) stake by 89% in Q2 2026, selling an estimated $531K and leaving 35,262 shares worth $59.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

Federated Hermes first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. The position peaked at $613K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Federated Hermes held 35,262 shares of Neumora Therapeutics worth $59.9K as of Q2 2026.
  • Federated Hermes sold 278,857 Neumora Therapeutics shares in Q2 2026, an estimated $531K.
  • Neumora Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1683 holding.
  • Federated Hermes first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Federated Hermes's Neumora Therapeutics position peaked at $613K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.